Slide

Your Partner in Life Sciences Transformation

The Dedham Group is a top-tier strategy consulting firm that will propel you to commercial success.

With robust data, highly specialized expertise, and 360-degree perspective on the stakeholder experience, we’re your partner for transforming commercial models, revamping market positioning, and ensuring better patient access to care.

Learn More

Unparalleled Results

Our expert think-tank cuts through the “noise” to unearth actionable insights and cross-functional strategic recommendations to shatter payer, provider, and patient access barriers.

Expert Insights

With over two decades of experience in the most complex healthcare categories, our dedicated teams of subject matter experts in biologics, small molecules, oncology, immunology, rare disease, and other specialty spaces are in a league of their own.

Consider us your preferred partners for strategic direction across payer, provider, distribution and support channels, with a focus in access, pathways, pricing, contracting, and customer engagement.

Let’s elevate your market access journey together.

Breaking Down Barriers,
One Client, One Story at a Time

From Policy to Practice: Strategically Navigating Maximum Fair Price Implementation

The Inflation Reduction Act’s (IRA) Maximum Fair Price (MFP) provision enables the Centers for Medicare & Medicaid Services to negotiate prices for highly utilized drugs, representing a transformative shift in Medicare’s approach to drug pricing. Starting in 2026, MFPs will take effect for 10 high-volume Part D drugs and will expand in subsequent years to include additional Part D and Part B drugs. The magnitude of negotiated discounts is significant, with an average discount of over 50% for first-round drugs that treat diabetes, cardiovascular diseases, autoimmune diseases, and blood cancers.

What Gastroenterology Practice Consolidation Means for Pharma Manufacturers

As MSOs continue to shape the gastroenterology practice sector, pharma is adapting to address this evolving customer segment. Here's what these shifting dynamics mean for pharma manufacturers.

How Pathways Are Reshaping Community Oncology and Why Manufacturers Should Pay Attention

In 2024, the FDA issued over 60 oncology approvals, sustaining the high bar set by the agency in recent years. While encouraging, this influx of novel products and nuanced clinical data leaves generalist oncologists grappling with which regimens to keep in their treatment arsenal.

How Healthcare Systems Can Support Cell and Gene Therapy Growth

With the rapid increase in approvals for cell and gene therapy (CGT) products, a critical question emerges: does our healthcare system have the capacity to meet the growing patient demand? The CGT pipeline is continually expanding, with nearly 3,000 assets in development from preclinical through pre-registration phases, according to a report from ASGCT and our sister company, Citeline.

Four Strategies for Competing in the Crowded Obesity Drug Marketplace

Over 100 million Americans are classified as medically overweight, making obesity one of the fastest growing public health issues in the U.S. The anti-obesity medication (AOM) marketplace is rapidly expanding, with analysts estimating it to be worth $150 billion by 2032, fueled by the increasing demand for effective weight management (e.g., 15-25% weight loss) and metabolic health solutions. With potential Medicare coverage on the horizon and increasing patient demand, the obesity space promises to grow at an unprecedented rate.

Broadening Access to CAR-T Through the Community – What is Holding Us Back and What is Needed?

By Katie Moses, Associate Partner, Director of Cell and Gene Therapy Strategy CAR-T therapy has revolutionized oncology care and paved the way for innovation. Although CAR-T therapy access has historically been confined to large academic centers and sophisticated community health systems with inpatient capabilities, a growing opportunity exists for broader adoption within community practices. CAR-T […]

How Bispecific Antibody Therapies are Impacting Community Practices, and Three Trends to Watch

By Casey Speer, Principal, and Miranda Brekke, Senior Consultant As the oncology and hematology landscapes continue to evolve with the development of more complex therapies and competitive treatment options, bispecific antibody therapies (BsAbs) have emerged as a key player, particularly in the multiple myeloma and lymphoma markets. Importantly, there are key differences in the adoption […]

Overcoming Five Major Challenges in Biopharma Forecasting

The phrase "forecasts are always wrong" is a common refrain in the biopharma industry—and for good reason. Over half of pre-commercial assets fail to meet their projected forecasts, yet forecasting remains an indispensable tool for strategic planning, investment decisions, and resource allocation.

Why U.S. Market Access Strategies Do Not Translate in Ex-U.S. Markets

As the U.S. is the largest pharmaceutical market by revenue, many pharmaceutical manufacturers have dedicated U.S.-specific departments and teams to support new therapy launches.

The Evolving Role of Oncology Clinical Pathways in Value-Based Care

In recent years, healthcare providers, payers, and policymakers have increasingly shifted focus from delivering volume-based care to delivering value-based care. This transition, moving from traditional fee-for-service to models that prioritize quality and efficiency, has created a need for care models that deliver high-quality care while managing costs.

Customer-Centric & Client-First

We prioritize your success, elevating your internal and external positioning to fuel commercial excellence.

Our relationship-driven business delivers a white-glove experience, with high-touch expert support in simplifying our complex access environment.

“With so much change and noise, it’s hard to focus our people and resources, and no one is closer to the customer than Dedham, which gives us a huge competitive edge on a daily basis.”

VP, Oncology Franchise

"The Dedham Group is very data-driven and their output is always actionable because they know how to help us implement…we rely heavily on them as a priority partner."

Executive Director, Market Access

Your Partner in Life Sciences Transformation

Your Partner in Life Sciences Transformation

Breaking Down Barriers, One Client, One Story at a Time

From Policy to Practice: Strategically Navigating Maximum Fair Price Implementation

What Gastroenterology Practice Consolidation Means for Pharma Manufacturers

How Pathways Are Reshaping Community Oncology and Why Manufacturers Should Pay Attention

How Healthcare Systems Can Support Cell and Gene Therapy Growth

Four Strategies for Competing in the Crowded Obesity Drug Marketplace

Broadening Access to CAR-T Through the Community – What is Holding Us Back and What is Needed?

How Bispecific Antibody Therapies are Impacting Community Practices, and Three Trends to Watch

Overcoming Five Major Challenges in Biopharma Forecasting

Why U.S. Market Access Strategies Do Not Translate in Ex-U.S. Markets

The Evolving Role of Oncology Clinical Pathways in Value-Based Care

Customer-Centric & Client-First

Breaking Down Barriers,
One Client, One Story at a Time